This massive meta-analysis of 484 randomized, double-blind, placebo-controlled trials (104,176 participants) quantified the blood pressure–lowering effects of major antihypertensive drug classes and their combinations. It introduces a new intensity-based classification system and an online calculator to predict BP-lowering efficacy based on drug, dose, and baseline BP.Study Design:484 trials, 104,176 participants5 major drug classes: ACE inhibitors, ARBs, β-blockers, calcium channel blockers (CCBs), and diureticsFocus: Placebo-corrected reduction in systolic BP (SBP)Mean baseline BP: 154/100 mm HgMean follow-up: 8.6 weeks Key Findings Monotherapy (Standard Dose):Average SBP reduction: 8.7 mm HgBy class:ACE inhibitors: 6.8 mm HgARBs: 8.5 mm Hgβ-blockers: 8.9 mm HgCCBs: 9.5 mm HgThiazide diuretics: 10.8 mm Hg Dose Doubling:Adds ~1.5 mm Hg SBP reduction (except β-blockers, which add only ~0.5 mm Hg) Dual Therapy (Standard Dose of Each):Average SBP reduction: 14.9 mm HgDose doubling adds ~2.5 mm Hg more Triple Therapy:SBP reduction: Up to 22.5 mm Hg (quadruple therapy even higher in one trial)